Innovation and progress, perseverance and a commitment to excellence – another achievement! Recently, our company's Class 4 chemical drug, Peramivir Sodium Chloride Injection, received a Drug Registration Certificate issued by the National Medical Products Administration. This is considered equivalent to passing the consistency evaluation of generic drug quality and efficacy, further authoritative recognition of our R&D capabilities. Details are as follows:
Basic information about drugs

Generic name of the drug: Peramivir Sodium Chloride Injection
English name: Peramivir and Sodium Chloride Injection
Dosage form: Injection
Specifications: 100ml: Peramivir (calculated as C 15 H 28 N 4 O 4 ) 0.15g and Sodium Chloride 0.9g
Registration Category: Class 4 Chemical Drugs
Listing Authorization Holder: Nanjing Hengdao Pharmaceutical Technology Co., Ltd.
Drug Approval Number: National Drug Approval Number H20263763

Indications:

Used for influenza A or B. For the treatment of influenza A and B (peramivir is effective in treating influenza A and B, but clinical data on its use in influenza B is limited). Patients should use it within 48 hours of the first appearance of symptoms.

Market situation :

Peramivir is currently the only marketed antiviral drug administered intravenously, providing a reliable treatment pathway for patients who have difficulty with oral administration, develop drug resistance, or are at high risk of severe illness or complications. This product is included in Category B of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025). According to the Moshang Pharmaceutical Database, sales of this product in hospitals across all terminals exceeded 1 billion yuan in 2024, and sales exceeded 600 million yuan in the first half of 2025.
https://mp.weixin.qq.com/s/ZWVNMIIHLPk6FuxYpuiqxQ